文献速递胃肠外科

腹腔镜辅助与开放远端胃切除术治疗进展期胃癌的随机II期多中心临床试验(COACT 1001)

Laparoscopy-assisted versus Open D2 Distal Gastrectomy for Advanced Gastric Cancer: Results From a Randomized Phase II Multicenter Clinical Trial (COACT 1001).
PubMed 文献 · Ann Surg · 2018-01-01

该随机II期多中心试验比较腹腔镜辅助远端胃切除术(LADG)与开放远端胃切除术(ODG)治疗进展期胃癌的可行性。主要终点为淋巴结清扫的不符合率,LADG组与ODG组分别为47.0%和43.2%,无显著差异(P=0.648)。结论认为LADG对进展期胃癌可行,但亚组分析提示III期患者需进一步研究。

要点

  • LADG与ODG的D2淋巴结清扫不符合率无显著差异(47.0% vs 43.2%,P=0.648)。
  • 临床III期亚组中LADG不符合率显著高于ODG(52.0% vs 25.0%,P=0.043)。
  • 两组3年无病生存率无显著差异(LADG 80.1% vs ODG 81.9%,P=0.448)。

核心结论

  • 基于D2淋巴结清扫不符合率,LADG治疗进展期胃癌是可行的。
  • 亚组分析提示III期胃癌患者需进一步研究。

研究设计与样本

  • 随机、非盲、多中心II期临床试验,采用固定区组大小1:1分配。
  • 纳入cT2-T4a和cN0-2(AJCC第7版)远端胃癌患者,2010年6月至2011年10月共204例入组并接受LADG(n=105)或ODG(n=99)。
  • 意向性治疗分析纳入196例(LADG 100例,ODG 96例)。

主要发现

  • 总体淋巴结清扫不符合率LADG组47.0%,ODG组43.2%,差异无统计学意义(P=0.648)。
  • 临床III期亚组中,LADG组不符合率52.0%,ODG组25.0%,差异有统计学意义(P=0.043)。
  • 3年无病生存率LADG组80.1%,ODG组81.9%,差异无统计学意义(P=0.448)。
  • 术后并发症发生率及手术应激反应两组间差异均无统计学意义。

临床怎么用

  • LADG可作为进展期胃癌的可行术式,但III期患者应谨慎选择并优先考虑进一步研究背景。

局限性

  • II期试验样本量有限,主要终点为不符合率而非长期生存。
  • 研究未设盲,可能存在偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This randomized, phase II, multicenter clinical trial was conducted to evaluate the feasibility of laparoscopy-assisted distal gastrectomy (LADG) with D2 lymph node dissection compared with open distal gastrectomy (ODG) for the treatment of advanced gastric cancer (AGC). SUMMARY OF BACKGROUND DATA: D2 lymph node dissection has been accepted as standard treatment for AGC. Although LADG is widely performed in early gastric cancer (EGC), the feasibility of LADG in AGC has not been proven yet. METHODS: Patients with cT2-T4a and cN0-2 (AJCC 7 staging system) distal gastric cancer were randomly but not blindingly assigned to LADG or ODG groups using fixed block sizes with a 1:1 allocation ratio. The primary endpoint was the noncompliance rate of the lymph node dissection, which was used to evaluate feasibility. Secondary endpoints included 3-year disease-free survival (DFS), 5-year overall survival, complications, and surgical stress response. RESULTS: Between June 2010 and October 2011, 204 patients enrolled and underwent either LADG (n = 105) or ODG (n = 99). Of these, 196 patients (100 in LADG and 96 in ODG) were included in the intention-to-treat analysis. There were no significant differences in the overall noncompliance rate of lymph node dissection between LADG and ODG groups (47.0% and 43.2%, respectively; P = 0.648). In the subgroup analysis, the noncompliance rate in the LADG group was significantly higher than the ODG group for clinical stage III disease (52.0% vs 25.0%, P = 0.043). No difference was found in the 3-year DFS rate between the groups (LADG, 80.1%; ODG, 81.9%; P = 0.448). Differences in postoperative complication rates and surgical stress response were found to be insignificant between the 2 arms. CONCLUSIONS: LADG was feasible for AGC treatment based on the noncompliance rate of D2 lymph node dissection. Subgroups analysis data suggest that further studies are needed for stage III gastric cancer.

来源:Ann Surg,查看原文。版权归原作者所有。

引用

  1. Park YK, Yoon HM, Kim YW, et al. Laparoscopy-assisted versus Open D2 Distal Gastrectomy for Advanced Gastric Cancer: Results From a Randomized Phase II Multicenter Clinical Trial (COACT 1001). Ann Surg. 2018. PMID: 28187041. doi:10.1097/SLA.0000000000002168

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。